Jamie Dananberg Sells 5,521 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,521 shares of Annexon stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $2.96, for a total value of $16,342.16. Following the completion of the transaction, the insider now directly owns 33,479 shares in the company, valued at $99,097.84. This represents a 14.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Annexon Stock Performance

Annexon stock opened at $2.83 on Friday. The business’s 50-day simple moving average is $4.29 and its 200-day simple moving average is $5.57. The firm has a market capitalization of $301.66 million, a PE ratio of -2.70 and a beta of 1.07. Annexon, Inc. has a 52 week low of $2.63 and a 52 week high of $8.40.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Annexon currently has an average rating of “Buy” and an average target price of $15.80.

Institutional Investors Weigh In On Annexon

Several hedge funds and other institutional investors have recently modified their holdings of ANNX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Annexon in the fourth quarter valued at $252,000. TFG Asset Management GP Ltd lifted its position in Annexon by 78.5% during the 4th quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after buying an additional 615,645 shares in the last quarter. Shay Capital LLC bought a new stake in shares of Annexon during the fourth quarter valued at approximately $159,000. Sphera Funds Management LTD. acquired a new stake in shares of Annexon in the 4th quarter valued at $6,377,000. Finally, Rafferty Asset Management LLC raised its holdings in Annexon by 23.5% during the 4th quarter. Rafferty Asset Management LLC now owns 218,369 shares of the company’s stock worth $1,120,000 after purchasing an additional 41,544 shares during the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.